Expert Interview
Discussing the approval of Enhertu as the first HER2-directed therapy in patients with HER2-low metastatic breast cancer
Ticker(s): AZNInstitution: UC San Diego Health
- Associate professor of Clinical Medicine and Scientific Director of Inflammatory and Triple Negative Breast Cancer Program at UC San Diego Health.
- Principal investigator of many clinical trials and is part of the national clinical operations leadership for the I-SPY-2 trial focusing on the treatment of triple negative breast cancer.
- Has published numerous papers on the topic of metastatic breast cancer in in JAMA Oncology, Cancer Cell and Molecular Cancer Therapeutics, among others.
- Manages over 300 patients with HER2 low breast cancer and currently prescribes Enhertu
How many patients with HER2- low metastatic breast cancer do you manage?
Added By: dami_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for Enhertu in this treatment population?
How many breast cancer patients do you manage? How many would you estimate are metastatic with HER-2 low status?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
